Neoadjuvant therapy for hepatocellular carcinoma / 国际外科学杂志

Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence rate and mortality in the world. Surgical resection is the main radical method. However, the high recurrence rate leads to poor prognosis. Neoadjuvant therapy refers to anti-tumor therapy for resectable HCC before surgery to reduce tumor load and postoperative recurrence. Although more and more studies show that neoadjuvant therapy can bring survival benefits to patients with liver cancer. However, the indication, applicable population, treatment mode, treatment cycle and safety of new adjuvant therapy are still controversial. In this review, we will review the above issues, as well as the clinical application and research progress of neoadjuvant in hepatocellular carcinoma.

Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy for advanced hepatocellular carcinoma / 中华消化外科杂志

Primary liver cancer is one of the common malignant tumors and its mortality ranks third in the world. Because there are no obvious symptoms in the early stage of liver cancer, most patients are diagnosed as advanced stage, without the opportunity of surgical resection. The authors report a case of hepatocellular carcinoma with portal vein tumor thrombus, which reduced significantly after hepatic artery infusion chemotherapy combined with bevacizumab and atezolizumab, showing the safety and efficacy.